These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23375777)

  • 1. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
    Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
    Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
    Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
    Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.
    Golbourn B; Ho B; Bondoc A; Luck A; Fan X; Richardson E; Marcellus R; Prakesch M; Halbert M; Agrawal N; Smith C; Huang A; Rutka JT
    Neuro Oncol; 2024 Oct; 26(10):1895-1911. PubMed ID: 38981018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Goldman S; Geyer JR; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Neurooncol; 2013 Sep; 114(2):173-9. PubMed ID: 23836190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
    Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
    Ammoun S; Cunliffe CH; Allen JC; Chiriboga L; Giancotti FG; Zagzag D; Hanemann CO; Karajannis MA
    Neuro Oncol; 2010 Aug; 12(8):834-43. PubMed ID: 20511180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor.
    Giang LH; Wu KS; Lee WC; Chu SS; Do AD; Changou CA; Tran HM; Hsieh TH; Chen HH; Hsieh CL; Sung SY; Yu AL; Yen Y; Wong TT; Chang CC
    J Exp Clin Cancer Res; 2023 Dec; 42(1):346. PubMed ID: 38124207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
    Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
    Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
    Messerli SM; Hoffman MM; Gnimpieba EZ; Bhardwaj RD
    Mol Cancer Res; 2017 Aug; 15(8):973-983. PubMed ID: 28442586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
    Konecny GE; Venkatesan N; Yang G; Dering J; Ginther C; Finn R; Rahmeh M; Fejzo MS; Toft D; Jiang SW; Slamon DJ; Podratz KC
    Br J Cancer; 2008 Mar; 98(6):1076-84. PubMed ID: 18334972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
    Gorlick R; Kolb EA; Houghton PJ; Morton CL; Phelps D; Schaiquevich P; Stewart C; Keir ST; Lock R; Carol H; Reynolds CP; Maris JM; Wu J; Smith MA
    Pediatr Blood Cancer; 2009 Oct; 53(4):594-8. PubMed ID: 19554571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells.
    D'cunja J; Shalaby T; Rivera P; von Büren A; Patti R; Heppner FL; Arcaro A; Rorke-Adams LB; Phillips PC; Grotzer MA
    Eur J Cancer; 2007 Jul; 43(10):1581-9. PubMed ID: 17446062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical teratoid/rhabdoid tumor of the CNS: cytopathology and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1, cathepsin D, and Ki-67.
    Ogino S; Cohen ML; Abdul-Karim FW
    Mod Pathol; 1999 Apr; 12(4):379-85. PubMed ID: 10229502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
    Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
    BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.
    Venkataraman S; Alimova I; Tello T; Harris PS; Knipstein JA; Donson AM; Foreman NK; Liu AK; Vibhakar R
    J Neurooncol; 2012 May; 107(3):517-26. PubMed ID: 22246202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
    Havaleshko DM; Smith SC; Cho H; Cheon S; Owens CR; Lee JK; Liotta LA; Espina V; Wulfkuhle JD; Petricoin EF; Theodorescu D
    Neoplasia; 2009 Nov; 11(11):1185-93. PubMed ID: 19881954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
    Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
    Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
    Knipstein JA; Birks DK; Donson AM; Alimova I; Foreman NK; Vibhakar R
    Neuro Oncol; 2012 Feb; 14(2):175-83. PubMed ID: 22156471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.